用于疾病治疗的 RIPK2 抑制剂:目前的状况和前景
Erkang Tian1, Changhan Zhou1, Shuqi Quan1
1State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases & Department of Orthodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, China.
European journal of medicinal chemistry
|August 2, 2023
概括
受体相互作用蛋白激酶2 (RIPK2) 是免疫和亡的一个关键分子. 本综述探讨了RIPK2的研究.
科学领域:
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
- 生物化学 生物化学
背景情况:
- 受体相互作用蛋白激酶2 (RIPK2) 是一种在人体组织中广泛表达的细胞质蛋白.
- 它在先天性和适应性免疫中充当双特异性激酶和适应分子.
- RIPK2在托尔类受体 (TLR) 和核酸结合寡合化域 (NOD) 信号通路中发挥作用.
研究的目的:
- 审查RIPK的分子结构和生物功能2.2.
- 检查RIPK2与人类疾病之间的相关性.
- 专注于RIPK2的小分子抑制剂,它们的结构-活性关系和治疗潜力.
主要方法:
- 对RIPK2结构,功能和疾病相关性的文献综述.
- 对RIPK2抑制剂的结构活性关系的分析.
- 在疾病背景下评估治疗潜力.
主要成果:
- RIPK2与瘤亡因子受体 (TNFR) 相互作用,在免疫信号传递中至关重要.
- RIPK2的失调与炎症反应,自身免疫性疾病和瘤有关.
- 针对RIPK2的小分子抑制剂显示出治疗前景.
结论:
- RIPK2是各种疾病治疗干预的重要分子标.
- 了解RIPK2的结构-活性关系是开发有效小分子抑制剂的关键.
- 针对RIPK2的疗法有可能用于治疗炎症,自身免疫疾病和癌症.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
205
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
205
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Drug Administration and Therapy Phases: Overview
540
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
540


